Core Viewpoint - The innovative drug sector is expected to continue as a strong investment theme, with significant clinical data releases from Chinese innovative drugs anticipated in the upcoming months, coinciding with a peak season for licensing agreements with multinational pharmaceutical companies [1] Group 1: Market Performance - BeiGene (ONC.US) saw a 6% increase in stock price, reaching $338.19 [1] - The innovative drug sector is projected to maintain rapid revenue growth and a trend of reduced losses year-on-year, with some leading companies approaching breakeven points [1] Group 2: Upcoming Events - Major conferences such as the World Lung Cancer Conference, European Society for Medical Oncology, and American Society of Hematology are scheduled for the second half of the year, where key clinical data for Chinese innovative drugs will be presented [1] Group 3: International Collaboration - There is an increasing trend of active licensing transactions for Chinese innovative drugs, with both the number and value reaching new highs [1] - Global multinational pharmaceutical companies are expected to focus more on Chinese pipelines as many blockbuster drug patents will expire in the next two to three years, creating a demand for new research pipelines [1]

Core Viewpoint - The innovative drug sector is expected to continue its strong performance, with significant clinical data releases from Chinese innovative drugs at major conferences in the latter half of the year, potentially leading to a market surge similar to the one seen in May at the American Oncology Conference [1] Group 1: Market Performance - BeiGene (ONC.US) shares rose by 6%, reaching $338.19 [1] - The innovative drug sector is anticipated to maintain high revenue growth and a trend of reduced losses year-on-year, with some leading companies approaching breakeven [1] Group 2: Upcoming Events - Major conferences such as the World Lung Cancer Conference, European Oncology Congress, and American Hematology Annual Meeting are set to showcase key clinical data for Chinese innovative drugs [1] Group 3: International Collaboration - There is an increase in licensing negotiations between Chinese companies and multinational corporations (MNCs), with several potential blockbuster drugs entering advanced negotiation stages [1] - The next two to three years will see a significant number of patent expirations for major drugs from global pharmaceutical companies, creating opportunities for Chinese innovative drugs to fill the gaps [1] Group 4: Industry Outlook - The innovative drug sector is experiencing a rise in international recognition for its innovative capabilities, with active licensing transactions reaching new highs in both quantity and value [1] - Increased collaboration between multinational pharmaceutical companies and Chinese firms is expected to enhance market valuation expectations for the innovative drug sector [1]

Core Viewpoint - The innovative drug sector is expected to continue its strong growth trajectory, with significant clinical data releases and potential licensing agreements on the horizon, particularly for Chinese companies [1] Group 1: Market Performance - BeiGene (ONC.US) saw a 6% increase in stock price, reaching $338.19 [1] - The innovative drug sector is highlighted as the strongest investment theme, with expectations for sustained performance [1] Group 2: Upcoming Events - Major conferences such as the World Lung Cancer Conference, European Society for Medical Oncology, and American Society of Hematology are set to showcase key clinical data for Chinese innovative drugs in the latter half of the year [1] - The end of the year is anticipated to bring a peak in licensing activities from multinational pharmaceutical companies, with several Chinese potential BICs in advanced negotiations [1] Group 3: Financial Outlook - The innovative drug sector is projected to maintain high revenue growth and a trend of reduced losses year-on-year, with some leading companies approaching breakeven points [1] - The overall industry is showing signs of improving profitability [1] Group 4: International Expansion - Chinese innovative drugs are gaining international recognition for their innovative capabilities, with a surge in outbound licensing transactions in terms of both quantity and value [1] - In the next two to three years, a significant number of blockbuster drug patents from global pharmaceutical companies will expire, creating a demand for new research pipelines [1] - Increased collaboration between multinational companies and Chinese firms is expected to enhance market valuation expectations for the innovative drug sector [1]

Group 1 - The pharmaceutical sector has regained momentum, with A-shares in innovative drugs showing strong recovery, particularly the drug ETF (562050) which surged by 3.36%, reaching a record closing high [1] - The Hong Kong stock market saw even greater gains in innovative drugs, with the Hong Kong Stock Connect innovative drug ETF (520880) rising by 4.52%, also hitting a new closing high [1][3] - The innovative drug ETF (520880) currently covers 29 innovative drug concept stocks, all of which have shown positive performance, with notable increases in stocks like Sanofi and Kintor Pharmaceuticals [3] Group 2 - The innovative drug ETF (520880) will undergo a "purification" revision on September 8, 2023, removing CXO companies and focusing solely on innovative drug R&D firms, thus becoming a 100% pure innovative drug index [3] - As of September 3, 2023, the cumulative year-to-date increase for the index tracked by the innovative drug ETF (520880) reached 118.95%, leading among similar indices [3][4] - The Hang Seng Innovative Drug Select Index has shown significant fluctuations in past years, with a notable increase in 2023, indicating a potential upward trend in the innovative drug sector [5] Group 3 - Upcoming key academic conferences, including the World Lung Cancer Conference and the European Oncology Congress, are expected to catalyze further developments in the innovative drug sector [5] - The medical ETF has a total scale of 26.325 billion yuan, making it the largest medical ETF in the market [5]

Core Viewpoint - The article discusses the quarterly review changes of the FTSE China A50 index announced by FTSE Russell, highlighting the inclusion and exclusion of specific stocks and the implications for investment funds tracking the index [5][6]. Group 1: Index Changes - Four stocks, including BeiGene, NewEase, WuXi AppTec, and Zhongji Xuchuang, will be added to the FTSE China A50 index, while China Nuclear Power, China Unicom, Guodian NARI, and Wanhua Chemical will be removed [5]. - The newly added stocks belong to the innovative drug and CPO sectors, while the removed stocks are from traditional industries such as utilities and telecommunications [5]. - The newly included stocks have shown significant price increases this year, with NewEase and Zhongji Xuchuang rising over 200%, and BeiGene and WuXi AppTec around 90% [5]. Group 2: Market Impact - The estimated size of passive funds tracking the FTSE China A50 index exceeds $10 billion, indicating that changes in constituent stocks can lead to substantial capital flows, potentially in the hundreds of millions to billions [5]. - Investors have raised concerns about the inclusion of stocks perceived as overvalued and whether this adjustment is a strategy for foreign capital to take over high-priced stocks [6]. - The adjustment is based on market capitalization and liquidity criteria, with the review conducted quarterly, using data from the third Friday of February, May, August, and November [6].

Group 1 - The A-share market is experiencing a correction, particularly in the pharmaceutical sector, with leading innovative drug companies like Huadong Medicine and BeiGene dropping over 5% [1] - The Hong Kong market's innovative drug ETF (520880) saw a significant decline of 3.32% after a previous rally, indicating a volatile trading environment [1][3] - The innovative drug ETF (520880) has accumulated over 6.2 billion yuan in net inflows over the past 60 days, reflecting strong investor interest despite recent market fluctuations [3][5] Group 2 - Upcoming major conferences, such as the World Lung Cancer Conference, are expected to catalyze a rebound in the innovative drug sector, with companies like CanSino Biologics and BeiGene presenting new research [5] - The innovative drug sector is anticipated to benefit from global competitiveness, overseas expansion, and supportive policies, which are expected to reshape valuations [5] - The Hong Kong innovative drug ETF (520880) is set to revise its index to focus solely on innovative drug research companies, enhancing its purity and potential performance [6] Group 3 - The innovative drug ETF (520880) has shown a remarkable year-to-date increase of 118.95%, outperforming other indices in the sector [8] - The medical ETF market is currently valued at 271.33 billion yuan, making it the largest in the pharmaceutical and medical category [10]

Core Points - BeOne Medicines Ltd. announced a new subscription period for its 2018 Employee Stock Purchase Plan, which will run from September 2, 2025, to February 27, 2026 [1] - Eligible employees can purchase shares at a price equal to 85% of the fair market value on the first or last trading day of the subscription period [1] - The plan aims to align employee interests with those of shareholders and encourage retention [1] Subscription Period Details - Application period: August 18, 2025, to August 31, 2025 [1] - Subscription period: September 2, 2025, to February 27, 2026 [1] - Eligible employees must be employed on the first day of the subscription and cannot hold 5% or more voting rights after exercising their purchase rights [1] Participation and Financial Details - A total of 4,693 eligible employees are expected to participate in the plan [1] - Employees can contribute between 1% and 10% of their qualified income, with a maximum annual contribution of $25,000 [1] - As of September 2, 2025, there will be 3,998,286 shares available for issuance under the plan [1]

致：香港交易及結算所有限公司 公司名稱: 百濟神州有限公司 (根據瑞士法律註冊成立的公司) 呈交日期: 2025年9月4日 股份發行人及根據《上市規則》第十九B章上市的香港預託證券發行人的證券變動月報表 截至月份: 2025年8月31日 狀態: 新提交 I. 法定/註冊股本變動 | 1. 股份分類 | 普通股 | 股份類別 | 不適用 | | 於香港聯交所上市 (註1) | | 是 | | | --- | --- | --- | --- | --- | --- | --- | --- | --- | | 證券代號 (如上市) | 06160 | 說明 | 請見備注 | | | | | | | | | 法定/註冊股份數目 | | | 面值 | | 法定/註冊股本 | | | 上月底結存 | | | 2,311,463,847 | USD | 0.0001 | USD | | 231,146.38 | | 增加 / 減少 (-) | | | 0 | | | USD | | 0 | | 本月底結存 | | | 2,311,463,847 | USD | 0.0001 | USD | | 231,146.38 | 本 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 1 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 授出受限制股份單位 授出日期： 2025年8月29日 承授人數目： 二百零二名 已授出受限制股份單位 涉及的相關股份數目： 474,630 受限制股份單位總數 （美國存託股份）: 36,510 本公告乃根據上市規則第17.06A、17.06B以及17.06C條作出。於2025年8月29 日，董事會薪酬委員會根據2016期權及激勵計劃的條款向二百零二名承授人授出 涉及合共36,510股美國存託股份的受限制股份單位。 2016期權及激勵計劃項下的受限制股份單位 於2025年8月29日，董事會薪酬委員會根據2016期權及激勵計劃的條款授予二百 零二名承授人合共36,510股美國存託股份受限制股份單位。該等受限制股份單位 相當於474,630股股份，約佔本公告之日公司發行股份總數的0.03%。 ...

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性 或完整性亦不發表任何聲明，並明確表示概不就因本公告全部或任何部分內容而產生或因依賴 該等內容而引致的任何損失承擔任何責任。 BeOne Medicines Ltd. 百濟神州有限公司 （根據瑞士法律註冊成立的公司） （股份代號：06160） 員工購股計劃 合資格僱員在每個認購期開始前，於申請期內登記該 認購期。 參與人數： 截至申請期結束，參與2018員工購股計劃的合資格僱 員共計4,693人。參與員工可在認購期隨時退出參與 2018員工購股計劃。 2018員工購股計劃使合資格僱員可按市價15%折讓申購股份（包括以美國存託股 份的形式）。僱員可於認購期結束後購買股份，購股資金可從其認購期內所得薪金 中扣除。2018員工購股計劃由董事會薪酬委員會管理。 認購期詳情 2018員工購股計劃項下的認購期通常從每年3月1日及 9月1日開始，持續六個月，除非董事會薪酬委員會提 前另行決定。就上市規則第17章而言，認購期被視為 歸屬期。 資格： 於適用認購的首日受僱於且於有關認購的申請期開始 時已受僱於本公司及指定子公司的所有僱員均具資格 ...